ArticleInternational journal of oncology2007
RNAi-mediated abrogation of cathepsin B and MMP-9 gene expression in a malignant meningioma cell line leads to decreased tumor growth, invasion and angiogenesis.
Article in International journal of oncology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Meningioma animal models: a systematic review and meta-analysis.Journal of translational medicine · 2023Pooled it
- Article
- Schnurri-3 drives tumor growth and invasion in cancer cells expressing interleukin-13 receptor alpha 2.Cell death & disease · 2023Article
- The Role of Cysteine Protease Cathepsins B, H, C, and X/Z in Neurodegenerative Diseases and Cancer.International journal of molecular sciences · 2023Review
- Smart Delivery Systems Responsive to Cathepsin B Activity for Cancer Treatment.Pharmaceutics · 2023Review
- Review
- Molecular neuropathology of brain-invasive meningiomas.Brain pathology (Zurich, Switzerland) · 2022Review
- Shared Gene Expression and Immune Pathway Changes Associated with Progression from Nevi to Melanoma.Cancers · 2021Article
- Mucin 1 as a Molecular Target of a Novel Diisoquinoline Derivative Combined with Anti-MUC1 Antibody in AGS Gastric Cancer Cells.Molecules (Basel, Switzerland) · 2021Article
- Brain-invasive meningiomas: molecular mechanisms and potential therapeutic options.Brain tumor pathology · 2021Review
- Integrated Analysis of ceRNA Regulatory Network Associated With Tumor Stage in Cervical Cancer.Frontiers in genetics · 2021Article
- Cathepsin B is highly expressed in pancreatic cancer stem-like cells and is associated with patients' surgical outcomes.Oncology letters · 2021Article
- Mechanism of action of Panax notoginoside against lung cancer in mice based on response to CTSB gene.BMC complementary medicine and therapies · 2020Article
- Cathepsin B defines leader cells during the collective invasion of salivary adenoid cystic carcinoma.International journal of oncology · 2019Article
- Expression of Cathepsins B, D, and G in WHO Grade I Meningioma.Frontiers in surgery · 2019Article
- Prognostic and therapeutic relevance of cathepsin B in pediatric acute myeloid leukemia.American journal of cancer research · 2019Article
- Identifying molecular mediators of environmentally enhanced neurogenesis.Cell and tissue research · 2018Review
- Expression and Therapeutic Potential of SOX9 in Chordoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017Article
- Role of Aquaporin 1 Signalling in Cancer Development and Progression.International journal of molecular sciences · 2017Review
- Pleomorphism and drug resistant cancer stem cells are characteristic of aggressive primary meningioma cell lines.Cancer cell international · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Malignant meningiomas are highly aggressive and frequently recur after surgical resection of the tumor. Earlier studies have reported that the cysteine protease cathepsin B and the matrix metalloproteinase MMP-9 play important roles in tumor progression. In the present study, we made an attempt to evaluate the roles of these proteases in the malignant meningioma tumor microenvironment and determined the effectiveness of using single or bicistronic siRNA constructs for cathepsin B and MMP-9, in both in vitro and in vivo models. Transfection of a plasmid vector expressing double-stranded RNA for cathepsin B and MMP-9 significantly inhibited mRNA and protein levels of cathepsin B and MMP-9. The migration and invasion of meningioma cells were decreased after treatment with single or bicistronic siRNA constructs for cathepsin B and MMP-9 compared to controls and vector controls. Inhibition of angiogenesis was observed when the cells were transfected with single or bicistronic constructs for cathepsin B and MMP-9, when compared to controls or empty vector controls. Our study revealed that abrogation of cathepsin B and MMP-9 expression decreased the activation of major proteins involved in MAP kinase and PI3 kinase pathways indicating that targeting these proteases may hinder intracellular signaling and thus decrease cell survival and proliferation in malignant meningiomas. In addition to the in vitro evidence, we observed a significant regression of pre-established orthotopic tumors after treatment with RNAi plasmid vectors targeting cathepsin B and MMP-9. Furthermore, these observations demonstrate that the simultaneous RNAi-mediated targeting of cathepsin B and MMP-9 has potential application for the treatment of human meningiomas.
Indexed as
Identifiers
17912429PMC2031211W1565366961What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.